Patents Assigned to PharmoRx Therapeutics, Inc.
  • Patent number: 9278094
    Abstract: The present invention relates to improved compositions and methods for the treatment or prevention of various diseases, including forms of depression, including, for example, breakthrough depression and treatment-refractory depression, and other mood disorders, as well as Parkinson's disease, bipolar disorder, bipolar disorder, attention deficit disorder (ADHD), Restless Leg Syndrome (RLS), and obesity. In some embodiments, the compositions and methods comprise low dose naltrexone or related opioid antagonists.
    Type: Grant
    Filed: March 5, 2015
    Date of Patent: March 8, 2016
    Assignee: PHARMORX THERAPEUTICS, INC.
    Inventors: David M. Bear, Robert M. Kessler
  • Publication number: 20150342946
    Abstract: The present invention relates to improved compositions and methods for the treatment or prevention of various diseases, including forms of depression, including, for example, breakthrough depression and treatment-refractory depression, and other mood disorders, as well Parkinson's disease, bipolar disorder, bipolar disorder, attention deficit disorder (ADHD), Restless Leg Syndrome (RLS), and obesity. In some embodiments, the compositions and methods comprise low dose naltrexone or related opioid antagonists.
    Type: Application
    Filed: January 30, 2014
    Publication date: December 3, 2015
    Applicant: PharmoRX Therapeutics, Inc.
    Inventors: David M Bear, Robert M. Kessler
  • Publication number: 20150080422
    Abstract: Methods and compositions are provided for preventing or reversing loss of the therapeutic effect of a drug, where the loss is associated with the repeated administration of the drug to a patient. The method includes administering to the patient a dopamine receptor agonist or partial agonist or a drug that increases the extracellular level of dopamine by enhancing release of dopamine, decreasing the removal of dopamine from the extracellular space, enhancing the synthesis of dopamine within the brain, or decreasing metabolic degradation of dopamine; and also administering to the patient an opioid receptor antagonist in an ultra-low dose amount, wherein the ultra-low dose amount is effective to prevent or reverse loss of therapeutic effects associated with the repeated administration of the drug to the patient. The methods are useful for various treatments, including treating Parkinson's Disease, Restless Leg Syndrome, depression, schizophrenia, psychostimulant drug abuse, or attention deficit disorder.
    Type: Application
    Filed: September 25, 2014
    Publication date: March 19, 2015
    Applicant: PharmoRx Therapeutics, Inc.
    Inventors: David M. Bear, Robert M. Kessler
  • Patent number: 8883831
    Abstract: Methods and compositions are provided for preventing or reversing loss of the therapeutic effect of a drug, where the loss is associated with the repeated administration of the drug to a patient. The method includes administering to the patient a dopamine receptor agonist or partial agonist or a drug that increases the extracellular level of dopamine by enhancing release of dopamine, decreasing the removal of dopamine from the extracellular space, enhancing the synthesis of dopamine within the brain, or decreasing metabolic degradation of dopamine; and also administering to the patient an opioid receptor antagonist in an ultra-low dose amount, wherein the ultra-low dose amount is effective to prevent or reverse loss of therapeutic effects associated with the repeated administration of the drug to the patient. The methods are useful for various treatments, including treating Parkinson's Disease, Restless Leg Syndrome, depression, schizophrenia, psychostimulant drug abuse, or attention deficit disorder.
    Type: Grant
    Filed: February 4, 2013
    Date of Patent: November 11, 2014
    Assignee: PharmoRx Therapeutics, Inc.
    Inventors: David M. Bear, Robert M. Kessler